Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Ranbaxy Defends A Drug Patent
by Jean-François Tremblay
September 30, 2013
| A version of this story appeared in
Volume 91, Issue 39
In a role reversal, the Indian firm Ranbaxy Laboratories will defend its U.S. patents on Absorica, an acne medication, against a challenge by Actavis, a Swiss generic drug maker. Absorica is an oral absorption capsule containing the active ingredient isotretinoin. It was developed by Ontario-based Cipher Pharmaceuticals, from which Ranbaxy licensed the rights. Actavis has filed an Abbreviated New Drug Application challenging two patents that Ranbaxy says expire in 2021. Ranbaxy is itself a frequent challenger of patents on drugs in the U.S. and other countries.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter